|
|
Post by lennymnkd on Nov 26, 2019 1:38:43 GMT -5
, would love to hear any rational basis for such a prediction / it’s called LUCK ,and luck does happen !
|
|
|
|
Post by myocat on Nov 26, 2019 11:01:12 GMT -5
$1.00 and sub within month or two is more real than $5 in 12 months. Sadly.
|
|
|
|
Post by letitride on Nov 26, 2019 20:32:01 GMT -5
I voted for 3 months because when a stock is as heavily manipulated down as this one is, in my opinion. It will have the ability to swing back in a big way in a short time in the opposite direction.The UTHR deal alone should have solidified this above five but here we sit at a dollar no problem I am still buying 3 months or 3 years I am going nowhere.
|
|
|
|
Post by brotherm1 on Nov 26, 2019 20:43:33 GMT -5
$1.00 and sub within month or two is more real than $5 in 12 months. Sadly. . I’m thinking with tax loss selling, we’ll see $1 and less again before end of December |
|
|
|
Post by goyocafe on Nov 26, 2019 20:56:41 GMT -5
$1.00 and sub within month or two is more real than $5 in 12 months. Sadly. . I’m thinking with tax loss selling, we’ll see $1 and less again before end of December And then MC can claim an even bigger % increase in share price when it gets back to $1.40. |
|
|
|
Post by bababooey on Nov 27, 2019 0:20:48 GMT -5
sayhey24 said the price would be over $10 once the SOC was updated. He confidently said without a doubt, Kendall would have the SOC changed before 2020. Now as the year comes to a close, not a peep from him. What will his excuse be next?
|
|
|
|
Post by mytakeonit on Nov 27, 2019 3:08:10 GMT -5
His excuse is that I've said that it will be at $10 at year end ... and he didn't want to be redundant.
But, that's mytakeonit
|
|
|
|
Post by sportsrancho on Nov 27, 2019 5:51:32 GMT -5
$1.00 and sub within month or two is more real than $5 in 12 months. Sadly. . I’m thinking with tax loss selling, we’ll see $1 and less again before end of December I agree that people will sell for their tax loss absolutely but maybe others will be buying. It’s the first quarter that the stock could move up based on the catalysts that are coming. But it’s December we’re going to miss those covenants. I said all that to say you could be right. |
|
|
|
Post by myocat on Nov 27, 2019 10:31:47 GMT -5
Jan 17 2020 3.00 call shows good Open Interest . Maybe that would help.
|
|
|
|
Post by agedhippie on Nov 27, 2019 10:48:18 GMT -5
Jan 17 2020 3.00 call shows good Open Interest . Maybe that would help. Be careful there. Two things to take into account; those are LEAPS so people probably bought them a year or more ago when things looked like 2019 might be the year, and second that open interest is the total number of open contracts regardless of if they are long or short. That's before you start looking at options strategies (straddles, strangles, etc.) where $3 Call is one side of the trade. My feeling is what the $1 and $3 Calls are telling you is that this is where the price was expected to land as the year progressed. Other ranges, say $2 to $5 were thinned out as it became clear that this range was likely to be a miss. |
|
|
|
Post by boca1girl on Nov 27, 2019 11:09:33 GMT -5
Jan 17 2020 3.00 call shows good Open Interest . Maybe that would help. Be careful there. Two things to take into account; those are LEAPS so people probably bought them a year or more ago when things looked like 2019 might be the year, and second that open interest is the total number of open contracts regardless of if they are long or short. That's before you start looking at options strategies (straddles, strangles, etc.) where $3 Call is one side of the trade. My feeling is what the $1 and $3 Calls are telling you is that this is where the price was expected to land as the year progressed. Other ranges, say $2 to $5 were thinned out as it became clear that this range was likely to be a miss. My 2020 leaps will expire worthless in Jan. I’m a bigger looser with MNKD leaps. Never again! |
|
|
|
Post by agedhippie on Nov 27, 2019 11:23:34 GMT -5
My 2020 leaps will expire worthless in Jan. I’m a bigger looser with MNKD leaps. Never again! I have sworn off LEAPS for the moment after I got caught badly a couple of years ago by the reverse split and had to unload them at a loss just ahead of the RS. |
|
|
|
Post by slugworth008 on Nov 27, 2019 12:55:10 GMT -5
TreT or the pediatric trial results would pop MNKD to five pretty quickly and perhaps would drive some short covering potentially pushing the PPS higher IMO. The real question is will the gains be held and built upon. It was self serving of Snakeofi to deem Afrezza commercially unviable because their focus was on Toujeo - which has been a total bust (good!). Had they really gotten behind Afrezza scripts and acceptance would be much higher by now IMO. I'm still shocked that another BP hasn't stepped in - then again who knows what offers or interest may have been tendered or expressed to MC? Toujeo and Afrezza were both launched at the same time, but in the last quarter Toujeo had net revenue of $232M last quarter against Afrezza's $6.4M. So not a total bust.  Perhaps not but it hasn't produced anything close to Lantus. Had Snakeofi paired up Afrezza with Toujeo perhaps it may have faired better? Then again WTF do I know - lol |
|
|
|
Post by agedhippie on Nov 27, 2019 13:37:30 GMT -5
Toujeo and Afrezza were both launched at the same time, but in the last quarter Toujeo had net revenue of $232M last quarter against Afrezza's $6.4M. So not a total bust. Perhaps not but it hasn't produced anything close to Lantus. Had Snakeofi paired up Afrezza with Toujeo perhaps it may have faired better? Then again WTF do I know - lol Toujeo suffers from the same problem that Afrezza does with RAA - if Lantus is working for you today (or you think it is) then why change to Toujeo? For the record I did change to Toujeo from Lantus and I did get a lot better results, plus I no longer needed to split my dose to get 24hr cover. I have since moved to Tresiba which gives a better result but is marginal over Toujeo. In fairness it was my endo who told me to use Toujeo or I would probably still be on Lantus. Never underestimate inertia! |
|
|
|
Post by rockstarrick on Nov 27, 2019 14:48:22 GMT -5
Perhaps not but it hasn't produced anything close to Lantus. Had Snakeofi paired up Afrezza with Toujeo perhaps it may have faired better? Then again WTF do I know - lol Toujeo suffers from the same problem that Afrezza does with RAA - if Lantus is working for you today (or you think it is) then why change to Toujeo? For the record I did change to Toujeo from Lantus and I did get a lot better results, plus I no longer needed to split my dose to get 24hr cover. I have since moved to Tresiba which gives a better result but is marginal over Toujeo. In fairness it was my endo who told me to use Toujeo or I would probably still be on Lantus. Never underestimate inertia! Just going by memory of possibly a rumor, but I did hear discussion about how the concentration of Toujeo was troublesome for some people. Maybe it increased insulin resistance, or sensitivity, but it seemed most liked tresiba better. I don’t know if this is a question or just babble, just wondering if you experienced anything like this. |
|
